A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
99mTc-MIP-1404 is a radioactive diagnostic imaging agent indicated for imaging men with
newly diagnosed prostate cancer whose biopsy indicates a histopathologic Gleason grade of ≤
3+4 severity and / or are candidates for active surveillance, but have planned to undergo
radical prostatectomy. In these patients, the results may be used to help estimate the risk
of a histopathologic Gleason grade of > 3+4. This Phase 3 study is designed to evaluate the
specificity and sensitivity of 99mTc-MIP-1404 to detect clinically significant prostate
cancer when compared to histopathology.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society